Pablo J. Mozas

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications

Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma.

Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma.

Journal: HemaSphere
Published: December 28, 2025

CD70 Overexpression at Diagnosis Predicts Relapse and supports dual CD19-CD70 CAR-T Therapy in Follicular Lymphoma.

CD70 Overexpression at Diagnosis Predicts Relapse and supports dual CD19-CD70 CAR-T Therapy in Follicular Lymphoma.

Journal: Blood
Published: December 05, 2025

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): A practical compartment-based review.

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): A practical compartment-based review.

Journal: Blood reviews
Published: December 04, 2025

Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma and Tuberculosis: A Rare Association With Diagnostic and Therapeutic Challenges.

Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma and Tuberculosis: A Rare Association With Diagnostic and Therapeutic Challenges.

Journal: Journal of medical cases
Published: November 18, 2025

Genomic heterogeneity in primary cutaneous follicular center lymphomas reveals different clinicopathological subgroups.

Genomic heterogeneity in primary cutaneous follicular center lymphomas reveals different clinicopathological subgroups.

Journal: HemaSphere
Published: October 10, 2025

Combining CAR T-Cell Therapy and Nivolumab to Overcome Immune Resistance in THRLBCL: A Case Report.

Combining CAR T-Cell Therapy and Nivolumab to Overcome Immune Resistance in THRLBCL: A Case Report.

Journal: International journal of molecular sciences
Published: July 31, 2025

Double refractory chronic lymphocytic leukemia: clinical scenarios and therapeutic strategies

Double refractory chronic lymphocytic leukemia: clinical scenarios and therapeutic strategies

Journal: Medicina clinica
Published: July 05, 2025

The expression of MALAT1 long non-coding RNA is associated with good prognosis in mantle cell lymphoma.

The expression of MALAT1 long non-coding RNA is associated with good prognosis in mantle cell lymphoma.

Journal: Scientific reports
Published: June 12, 2025

Discriminating activating, deactivating and resistance variants in protein kinases.

Discriminating activating, deactivating and resistance variants in protein kinases.

Journal: Genome medicine
Published: May 07, 2025

Letter to the Editor regarding 18F-FDG PET or PET/CT in detecting high-grade transformation of chronic lymphocytic leukaemia and indolent lymphomas: a systematic review and meta-analysis.

Letter to the Editor regarding 18F-FDG PET or PET/CT in detecting high-grade transformation of chronic lymphocytic leukaemia and indolent lymphomas: a systematic review and meta-analysis.

Journal: The British journal of radiology
Published: April 10, 2025

Efficacy and safety of the academic anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphoma.

Efficacy and safety of the academic anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphoma.

Journal: HemaSphere
Published: February 25, 2025

CD6 expression is an independent predictor of time to first treatment in chronic lymphocytic leukemia.

CD6 expression is an independent predictor of time to first treatment in chronic lymphocytic leukemia.

Journal: Haematologica
Published: February 13, 2025
Showing 1-12 of 62

Last Updated: 09/26/2026